指南与共识湿疹皮炎与荨麻疹

≥2岁儿童及青少年特应性皮炎的系统治疗:北欧专家意见德尔菲共识项目

Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2022-07-19

北欧19名专家通过两轮德尔菲流程对37条陈述达成完全或部分共识,建议对≥2岁重度且优化非系统治疗后仍未控制者使用系统治疗;推荐环孢素A短期使用(所有年龄)、度普利尤单抗或甲氨蝶呤长期使用(≥6岁)。

要点

  • 系统治疗推荐用于≥2岁、临床诊断明确的重度AD且优化非系统治疗后持续未控制者。
  • 推荐环孢素A短期使用(所有年龄),度普利尤单抗或甲氨蝶呤长期使用(≥6岁)。
  • 2-6岁儿童最佳长期系统治疗未达成共识,但新生物制剂和JAK抑制剂可能成为有利选择。

核心结论

  • 文章为儿童及青少年AD系统治疗提供实用建议,补充国际和区域指南。
  • 共识考虑当时可用的系统药物:硫唑嘌呤、环孢素A、度普利尤单抗、甲氨蝶呤、吗替麦考酚酯和口服糖皮质激素。

研究设计与样本

  • 来自北欧的19名医生因儿童AD管理专长被选中。
  • 采用两轮德尔菲流程,对37条陈述达成完全或部分共识。

主要发现

  • 系统治疗推荐用于≥2岁、临床诊断明确的重度AD且优化非系统治疗后持续未控制者。
  • 系统治疗应实现长期疾病控制并减少短期干预。
  • 推荐环孢素A短期使用(所有年龄)和度普利尤单抗或甲氨蝶呤长期使用(≥6岁)。
  • 2-6岁儿童最佳长期系统治疗未达成共识,但新生物制剂和JAK抑制剂可能成为有利选择。

关键数值与推荐

  • 系统治疗推荐用于≥2岁、临床诊断明确的重度AD且优化非系统治疗后持续未控制者。
  • 推荐环孢素A短期使用(所有年龄)。
  • 推荐度普利尤单抗或甲氨蝶呤长期使用(≥6岁)。
  • 2-6岁儿童最佳长期系统治疗未达成共识。

临床怎么用

  • 对≥2岁重度AD且优化非系统治疗后未控制者,可考虑系统治疗以实现长期疾病控制。
  • 所有年龄短期使用可选用环孢素A;≥6岁长期使用可选用度普利尤单抗或甲氨蝶呤。
  • 2-6岁儿童长期系统治疗选择尚未达成共识,新生物制剂和JAK抑制剂可能成为有利选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies including biologics and Janus kinase (JAK) inhibitors, recently approved for various ages in this indication. OBJECTIVES: This expert consensus aimed to provide practical recommendations within this advancing field to enhance clinical decision-making on the use of these and other systemics for children and adolescents aged ≥2 years with moderate-to-severe AD. METHODS: Nineteen physicians from Northern Europe were selected for their expertise in managing childhood AD. Using a two-round Delphi process, they reached full or partial consensus on 37 statements. RESULTS: Systemic therapy is recommended for children aged ≥2 years with a clear clinical diagnosis of severe AD and persistent disease uncontrolled after optimizing non-systemic therapy. Systemic therapy should achieve long-term disease control and reduce short-term interventions. Recommended are cyclosporine A for short-term use (all ages) and dupilumab or methotrexate for long-term use (ages ≥6 years). Consensus was not reached on the best long-term systemics for children aged 2-6 years, although new systemic therapies will likely become favourable: New biologics and JAK inhibitors will soon be approved for this age group, and more trial and real-world data will become available. CONCLUSIONS: This article makes practical recommendations on the use of systemic AD treatments for children and adolescents, to supplement international and regional guidelines. It considers the systemic medication that was available for children and adolescents with moderate-to-severe AD at the time this consensus project was done: azathioprine, cyclosporine A, dupilumab, methotrexate, mycophenolate mofetil and oral glucocorticosteroids. We focus on the geographically similar Northern European countries, whose healthcare systems, local preferences for AD management and reimbursement structures nonetheless differ significantly.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. de Graaf M, Janmohamed SR, Schuttelaar MLA, et al. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. J Eur Acad Dermatol Venereol. 2022. PMID: 35793471. doi:10.1111/jdv.18410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。